TABLE 6.

Detection of individual oncogenic genotypes by the Onclarity and GP-LMNX assays in the screening and enriched populations of the VALGENT4 panel

hrHPV genotype(s)	Screening population (n = 991)								Enriched population (n = 297)								VALGENT4 panel
	No. (%) with the following result(s)a :						Agreement	Kappa	No. (%) with the following result(s)a :						Agreement	Kappa
	Onc+	GP-LMNX+	Onc+, GP-LMNX+	Onc+, GP-LMNX–	Onc–, GP-LMNX+	Onc–, GP-LMNX–			Onc+	GP-LMNX+	Onc+, GP-LMNX+	Onc+, GP-LMNX–	Onc–, GP-LMNX+	Onc–, GP-LMNX–			Agreement	Kappa
HPV16	18 (1.8)	31 (3.1)	18	0	13	960	98.7	0.73	70 (23.6)	71 (23.9)	68	2	3	224	98.3	0.95	98.6	0.90
HPV18	11 (1.1)	28 (2.8)	11	0	17	963	98.3	0.56	20 (6.7)	22 (7.4)	19	1	3	274	98.7	0.90	98.4	0.73
HPV31	12 (1.2)	16 (1.6)	12	0	4	975	99.6	0.86	38 (12.8)	36 (12.1)	35	3	1	258	98.7	0.94	99.4	0.92
HPV45	11 (1.1)	18 (1.8)	9	2	9	971	98.9	0.62	24 (8.1)	25 (8.4)	24	0	1	272	99.7	0.98	99.1	0.84
HPV51	8 (0.8)	13 (1.3)	7	1	6	977	99.3	0.66	22 (7.4)	24 (8.1)	21	1	3	272	98.7	0.91	99.2	0.83
HPV52	17 (1.7)	11 (1.1)	11	6	0	974	99.4	0.78	31 (10.4)	21 (7.1)	21	10	0	266	96.6	0.79	98.8	0.79
HPV33/58	17 (1.7)	29 (2.9)	16	1	13	961	98.6	0.69	29 (9.8)	29 (9.8)	27	2	2	266	98.7	0.92	98.6	0.82
HPV56/59/66	23 (2.3)	20 (2.0)	16	7	4	964	98.9	0.74	38 (12.8)	29 (9.8)	28	10	1	258	96.3	0.82	98.3	0.79
HPV35/39/68	23 (2.3)	33 (3.3)	21	2	12	956	98.6	0.74	59 (19.9)	65 (21.9)	55	4	10	228	95.3	0.86	97.8	0.83
All 14 hrHPV genotypes	113 (11.4)	159 (16.0)	102	11	57	821	93.1	0.71	255 (85.9)	253 (85.2)	247	8	6	36	95.3	0.81	93.6	0.85

^aOnc, Onclarity assay; +, positive; –, negative.